Synonyms: EMD-12192 | EMD-121974
Compound class:
Peptide
Comment: Cilengitide is a cyclic RGD pentapeptide, first-in-class integrin inhibitor. It inhibits integrin αv-induced angiogenesis. It was investigated for anti-tumour activity. Glioblastoma was one of the cancers investigated [6], based on encouraging preclinical studies in animals [3-4,7].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Phase 2 clinical trial results indicate little clinical efficacy as a single-agent therapy for metastatic melanoma, despite treatment being well tolerated [2]. Phase 3 in glioblastoma has been completed (NCT00689221), but the drug showed no improved clinical efficacy when added to standard temozolomide chemoradiotherapy, and development was terminated as a result [5]. Orphan designation for glioma granted by the European Medicines Agency in 2004, was withdrawn at the request of the sponsor in 2013. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Cilengitide inhibits integrin αv-induced angiogenesis. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00689221 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status | Phase 3 Interventional | EMD Serono |